Pharmalucence Builds New Drug Production Facility in Massachusetts
06/04/2010
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
Project Announcements
NYX Linden Expands Linden, Tennessee, Manufacturing Operations
03/20/2023
Arcosa Wind Towers Plans Belen, New Mexico, Wind-Tower Manufacturing Plant
03/20/2023
The Federal Metal Company Plans North Little Rock, Arkansas, Manufacturing Plant
03/20/2023
Full Throttle Fulfillment Solutions Plans Liberty, Indiana, Operations
03/20/2023
Tex-Tech Industries Plans Winston-Salem, North Carolina, Manufacturing Plant
03/20/2023
Patten Seed Company Relocates-Plans Charleston, South Carolina, Corporate Headquarters
03/17/2023
Most Read
-
2022 Top States for Doing Business Provide an Environment for Business Growth
Q3 2022
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
The Top Investment Location Prospects for Aerospace Manufacturing
Q1 2023
-
Strategies to Overcome Intensifying Industrial Real Estate Challenges
Q1 2023
-
How Are Economic Developers Partnering to Solve Workforce Challenges?
Q1 2023
-
What in the World? FDI Trends to Watch in 2023
Q1 2023